Featured Research

from universities, journals, and other organizations

Research Studies Drug To Treat Brain Metastases

Date:
December 16, 2004
Source:
Northwestern University
Summary:
A Northwestern University cancer researcher is conducting a study that will compare the effects of whole brain radiation therapy with supplemental oxygen without or with EfaproxynTM (efaproxiral), an experimental radiation sensitizer, in participants with brain cancer originating from metastatic breast cancer.

CHICAGO --- A Northwestern University cancer researcher is conducting a study that will compare the effects of whole brain radiation therapy with supplemental oxygen without or with EfaproxynTM (efaproxiral), an experimental radiation sensitizer, in participants with brain cancer originating from metastatic breast cancer.

Related Articles


It is believed that efaproxiral may improve the improve the effectiveness of whole brain radiation therapy in brain metastases from breast cancer, according to Virginia Kaklamani, M.D., assistant professor of medicine in the division of hematology/oncology at the Northwestern University Feinberg School of Medicine.

Kaklamani is a researcher at The Robert H. Lurie Comprehensive Cancer Center of Northwestern University and a staff hematologist/oncologist at the Northwestern Medical Faculty Foundation and at Northwestern Memorial Hospital.

Results from an earlier study suggested that the addition of efaproxiral to whole brain radiation therapy doubled survival among patients with metastatic breast cancer and significantly improved their quality of life.

Brain metastases occur when tumors spread to the brain from the primary tumor site in another part of the body. Whole brain radiation therapy is used to relieve symptoms and prolong survival and is the standard of care for treating patients with brain metastases.

Breast cancer is the second most common cause of brain metastases after lung cancer, accounting for 14 to 20 percent of the total incidence of brain metastases.

Efaproxiral is the first synthetic small-molecule compound designed to “sensitize” oxygen-deprived areas of tumors prior to radiation therapy by facilitating release of oxygen from hemoglobin, the oxygen-carrying protein contained in red blood cells, and increasing the level of oxygen in tumors.

The presence of oxygen in tumors is an essential element for the effectiveness of radiation therapy in the treatment of cancer. By increasing tumor oxygenation at the time of treatment, efaproxiral may enhance the efficacy of standard radiation therapy. Unlike chemotherapies or other radiation sensitizers, efaproxiral does not have to cross the blood brain barrier or enter the tumor to be effective.

To qualify as a participant in this study, you must have brain metastases from breast cancer and not had any previous treatment for brain metastases, including brain surgery and any form of radiation to the brain. During study treatment, you may continue to receive all therapies except chemotherapy.

For information on the efaproxiral study, call 312-695-0320.


Story Source:

The above story is based on materials provided by Northwestern University. Note: Materials may be edited for content and length.


Cite This Page:

Northwestern University. "Research Studies Drug To Treat Brain Metastases." ScienceDaily. ScienceDaily, 16 December 2004. <www.sciencedaily.com/releases/2004/12/041203094506.htm>.
Northwestern University. (2004, December 16). Research Studies Drug To Treat Brain Metastases. ScienceDaily. Retrieved November 29, 2014 from www.sciencedaily.com/releases/2004/12/041203094506.htm
Northwestern University. "Research Studies Drug To Treat Brain Metastases." ScienceDaily. www.sciencedaily.com/releases/2004/12/041203094506.htm (accessed November 29, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Saturday, November 29, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Rural India's Low-Cost Sanitary Pad Revolution

Rural India's Low-Cost Sanitary Pad Revolution

AFP (Nov. 28, 2014) — One man hopes his invention -– a machine that produces cheap sanitary pads –- will help empower Indian women. Duration: 01:51 Video provided by AFP
Powered by NewsLook.com
Research on Bats Could Help Develop Drugs Against Ebola

Research on Bats Could Help Develop Drugs Against Ebola

AFP (Nov. 28, 2014) — In Africa's only biosafety level 4 laboratory, scientists have been carrying out experiments on bats to understand how virus like Ebola are being transmitted, and how some of them resist to it. Duration: 01:18 Video provided by AFP
Powered by NewsLook.com
WHO Says Male Ebola Survivors Should Abstain From Sex

WHO Says Male Ebola Survivors Should Abstain From Sex

Newsy (Nov. 28, 2014) — WHO cites four studies that say Ebola can still be detected in semen up to 82 days after the onset of symptoms. Video provided by Newsy
Powered by NewsLook.com
Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins